Ensysce Biosciences (ENSC) Revenue (2020 - 2025)

Ensysce Biosciences (ENSC) has reported Revenue for 6 consecutive years, with $493104.0 the latest figure, recorded in Q3 2025.

• On a quarterly basis, Revenue fell 85.58% year-over-year to $493104.0 in Q3 2025; TTM through Sep 2025 was $4.5 million, a 1.51% increase from a year earlier, with the FY2024 full-year figure at $5.2 million, up 133.58% from the prior year.
• Revenue was $493104.0 for Q3 2025 at Ensysce Biosciences, down from $1.4 million in the prior quarter.
• Over five years, Revenue peaked at $3.4 million in Q3 2024 and troughed at $181797.0 in Q2 2024.
• A 5-year average of $877865.6 and a median of $515032.0 in 2023 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 685.26% in 2024 and plunged 85.58% in 2025, its largest moves.
• Over 5 years, Revenue stood at $1.6 million in 2021, then fell by 12.34% to $1.4 million in 2022, then slumped by 64.07% to $515032.0 in 2023, then surged by 153.12% to $1.3 million in 2024, then tumbled by 62.18% to $493104.0 in 2025.
• The last three Revenue figures came in at $493104.0 (Q3 2025), $1.4 million (Q2 2025), and $1.3 million (Q1 2025), per Business Quant data.